Lung Cancer with KRAS/EGFR Mutations
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 November 2022) | Viewed by 16607
Special Issue Editor
Interests: translational research; cancer biology; neoadjuvant chemotherapy; PCR; KRAS; EGFR driver mutations; oral targeted therapy; ALK translocations and ROS1 rearrangements; liquid biopsy; NGS; exosomes; NanoString and RNA-Seq; neoantigens; vaccines
Special Issue Information
Dear Colleagues,
EGFR and KRAS mutations represent a large group of lung cancer patients. Unfortunately, the death toll from this disease remains extremely high, and the mechanisms of resistance remain elusive in clinical practice, despite an abundance of preclinical research and clinical trials. This Special Issue centers on deciphering new research diagnostics and therapeutic methods stemming from geographical variations in the incidence of KRAS and EGFR mutations (even between regions within the same country). Circular RNA is a new class of non-coding RNA, non-linear RNA, that remains largely uncharted. Novel circular RNA is discussed in this Special Issue, including the author’s own experience. New forms of intracellular organelles, biomolecular condensates, govern RAS/MAP signaling in ALK and RET fusions. Recent discoveries in such biomolecular condensates are highlighted by the authors within this issue. In the past, co-signaling has not been widely addressed. Herein, the article on co-signaling covers an unmet need for both clinical oncologists and laboratory researchers. Lung-cancer-derived organoids represent a promising new technology for drug sensitivity that helps to explore signaling pathways in greater depth. The issue also includes a cutting-edge article on the development of mRNA vaccines as adjuncts to immunotherapy. Other chapters focus on novel fields relevant to science and cancer management, such as lung macrobiome, macrophages, and circulating extracellular vesicles, as well as new forms of targeted therapy and new approaches to induce responses to immunotherapy in EGFR-mutant NSCLC.
Dr. Rafael Rosell
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- KRAS
- EGFR
- NSCLC
- circRNA
- non-linear RNA, RAS/MAP signaling
- ALK, RET
- biomolecular condensates
- co-signaling
- lung cancer derived organoids
- mRNA vaccines
- lung microbiome
- macrophages
- circulating extracellular vesicles